TerminatedPhase 2NCT00003471
Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma
Studying Low-grade astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Burzynski Research Institute
- Principal Investigator
- Stanislaw R. Burzynski, MD, PhDBurzynski Research Institute
- Intervention
- Antineoplaston therapy (Atengenal + Astugenal)(drug)
- Enrollment
- 7 target
- Eligibility
- 18-99 years · All sexes
- Timeline
- 1996 – 2003
Study locations (1)
- Burzynski Clinic, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003471 on ClinicalTrials.govOther trials for Low-grade astrocytoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT04576117A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade GliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE3NCT04166409A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade GliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE3NCT01649830Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade GliomaSun Yat-sen University